Dr. Dietmar W. Siemann

Dr. Dietmar W. Siemann's AcademicInfluence.com Rankings

Medical

#2440

World Rank

#2865

Historical Rank

Pharmacology

#248

World Rank

#292

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Dr. Dietmar W. Siemann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dr. Dietmar W. Siemann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. (2011) (448)
Differentiation and definition of vascular-targeted therapies. (2005) (266)
Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1 (2008) (243)
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. (2006) (239)
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) (2009) (237)
Vascular‐targeting therapies for treatment of malignant disease (2004) (209)
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy (2002) (165)
The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. (1977) (140)
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. (2010) (138)
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. (2002) (137)
Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. (1998) (131)
Vascular targeted therapies in oncology (2008) (117)
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. (2001) (114)
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. (2014) (110)
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. (2002) (108)
Cathepsin L targeting in cancer treatment. (2015) (107)
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). (2008) (106)
Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity (2006) (106)
Modification of chemotherapy by nitroimidazoles. (1984) (102)
Modulation of the tumor vasculature and oxygenation to improve therapy. (2015) (101)
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. (2009) (97)
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. (2006) (96)
Current development status of small-molecule vascular disrupting agents. (2006) (95)
Impact of hypoxia on the metastatic potential of human prostate cancer cells. (2011) (84)
Improved Tumor Response by Combining Radiation and the Vascular-Damaging Drug 5,6-Dimethylxanthenone-4-acetic Acid (2001) (83)
Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. (1991) (82)
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. (2004) (82)
Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. (1987) (81)
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. (1994) (81)
Heterogeneity of glutathione content in human ovarian cancer. (1989) (79)
Leukemia regression by vascular disruption and antiangiogenic therapy. (2010) (76)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitro (2010) (74)
Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. (1982) (72)
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. (2005) (71)
Early and late pulmonary toxicity in mice evaluated 180 and 420 days following localized lung irradiation. (1982) (70)
Cell cycle specific toxicity of the Hoechst 33342 stain in untreated or irradiated murine tumor cells. (1986) (69)
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. (1994) (69)
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. (2013) (68)
Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts (1996) (67)
Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. (2000) (66)
Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. (2002) (65)
Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. (1993) (63)
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. (2003) (61)
Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells (2011) (61)
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. (2016) (60)
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. (2009) (59)
Surfactant release as an early measure of radiation pneumonitis. (1983) (59)
Applicability of animal tumor data to cancer therapy in humans. (1988) (59)
Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. (2016) (59)
Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer--a possible indicator of chemosensitivity. (1989) (58)
Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation. (1981) (58)
E-cadherin plasticity in prostate cancer stem cell invasion. (2011) (57)
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells (2013) (56)
Cell‐based selection provides novel molecular probes for cancer stem cells (2013) (55)
Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer (2014) (55)
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. (2016) (54)
Newly discovered anti-inflammatory properties of the benzamides and nicotinamides (1999) (53)
Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer (2017) (52)
Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo (2002) (52)
Comparison of glutathione levels in rodent and human tumor cells grown in vitro and in vivo. (1988) (52)
In vivo combination of misonidazole and the chemotherapeutic agent CCNU. (1981) (49)
Smoking: the influence of carboxyhemoglobin (HbCO) on tumor oxygenation and response to radiation. (1978) (49)
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment (2020) (48)
Exercise and the Tumor Microenvironment: Potential Therapeutic Implications. (2018) (47)
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. (2003) (47)
Characterizing the tumor response to treatment with combretastatin A4 phosphate. (2007) (47)
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor (2002) (47)
Glutathione contents in human and rodent tumor cells in various phases of the cell cycle. (1988) (47)
Preclinical Evaluations of Therapies Combining the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate and Conventional Anticancer Therapies in the Treatment of Kaposi's Sarcoma (2002) (46)
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. (1997) (45)
In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. (1981) (45)
Tumor radiosensitization through reductions in hemoglobin affinity. (1986) (44)
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. (1994) (44)
Morphologic changes reflecting early and late effects of irradiation of the distal lung of the mouse: a review. (1982) (44)
Vascular targeting agents (2002) (42)
Temporal aspects of the action of ASA404 (vadimezan; DMXAA) (2010) (42)
Should direct measurements of tumor oxygenation relate to the radiobiological hypoxic fraction of a tumor? (1995) (42)
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells (2012) (41)
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94 (2016) (40)
The in vivo radiation response of an experimental tumor: the effect of exposing tumor-bearing mice to a reduced oxygen environment prior to but not during irradiation. (1979) (40)
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. (2015) (39)
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. (2005) (39)
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. (2006) (39)
Sequential effects of irradiation on the pulmonary surfactant system. (1982) (39)
The relationship between mouse arterial partial pressure of oxygen (PaO2) and the effectiveness of localized tumour irradiation. (1975) (39)
In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. (1993) (38)
Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. (1982) (37)
Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes. (1986) (37)
A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport. (1989) (36)
Effects of radiation on the mouse lung and potential induction of radiation pneumonitis (1981) (36)
Tumor oxygenation and cancer therapy-then and now. (2018) (36)
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model (2016) (35)
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole. (1984) (35)
Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. (1986) (35)
Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph. (1998) (34)
Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. (2004) (34)
Direct synchronization of cells from solid tumors by centrifugal elutriation. (1981) (33)
Preclinical studies of the novel vascular disrupting agent MN-029. (2005) (33)
Have Clinical Trials Properly Assessed c-Met Inhibitors? (2017) (33)
The tumor microenvironment: a double-edged sword. (1998) (32)
Targeting the tumor vasculature: a strategy to improve radiation therapy (2004) (31)
Predictive biochemical assays for late radiation effects. (1986) (31)
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. (2008) (30)
Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (II). Cell sorting. (1988) (30)
Education and Training for Radiation Scientists: Radiation Research Program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12–14, 2003 (2003) (30)
Activity of the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate in a Xenograft Model of AIDS-Associated Kaposi's Sarcoma (2002) (29)
Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck (2000) (29)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation (2012) (28)
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck (2005) (28)
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. (2013) (28)
Cell survival recovery kinetics in the KHT sarcoma following treatment with five alkylating agents and misonidazole. (1982) (28)
Combinations of radiation and misonidazole in a murine lung tumor model. (1981) (27)
Prediction of tumour sensitivity to 4-hydroperoxycyclophosphamide by a glutathione-targeted assay. (1991) (27)
Monitoring the treatment efficacy of the vascular disrupting agent CA4P. (2007) (27)
Radiation induced secretion of surfactant from cell cultures of type II pneumocytes: an in vitro model of radiation toxicity. (1984) (27)
Postoperative radiation therapy for squamous cell carcinoma of the head and neck. (2003) (26)
Stromal cells in breast cancer as a potential therapeutic target (2018) (26)
Glutathione as a determinant of cellular response to doxorubicin. (1988) (26)
Potentiation of cisplatin activity by the bioreductive agent tirapazamine. (1998) (24)
Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis (2014) (24)
Tumor Vasculature: a Target for Anticancer Therapies (2006) (24)
Therapeutic Significance of Microenvironmental Factors (2000) (24)
Axl signaling is an important mediator of tumor angiogenesis (2019) (24)
Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy. (1989) (23)
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 (2012) (23)
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. (2010) (23)
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. (2010) (23)
In situ radiation response and oxygen enhancement ratio of KHT sarcoma cells in various phases of the cell cycle. (1984) (22)
Morphological correlates of fractionated radiation of the mouse lung: early and late effects. (1994) (22)
Enhancement of radiation therapy by vascular targeting agents. (2002) (22)
MRI-Based Computational Model of Heterogeneous Tracer Transport following Local Infusion into a Mouse Hind Limb Tumor (2014) (22)
Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II. (1992) (21)
In vivo tumor response to single and multiple exposures of adriamycin. (1980) (21)
Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation (2011) (21)
Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut. (1982) (21)
Chemosensitizing AML cells by targeting bone marrow endothelial cells. (2016) (21)
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation (2011) (20)
Analysis of blood gas values in mice following pulmonary irradiation. (1980) (20)
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. (2013) (20)
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. (2015) (20)
DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione. (1995) (20)
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. (2006) (20)
Comparison of tumour age response to radiation for cells derived from tissue culture or solid tumours. (1984) (20)
Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069. (1984) (19)
Isolation by flow cytometry of a human ovarian tumor cell subpopulation exhibiting a high glutathione content phenotype and increased resistance to adriamycin. (1989) (19)
Thiol manipulation as a means of overcoming drug resistance in a novel cyclophosphamide-induced resistant cell line. (1992) (18)
Interleukin 1 alpha stimulates hemopoiesis but not tumor cell proliferation and protects mice from lethal total body irradiation. (1991) (18)
The interaction between adriamycin and radiation in a solid murine tumor. (1980) (18)
A semiquantitative probe for radiation-induced normal tissue damage at the molecular level. (1986) (18)
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. (1990) (18)
Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. (1997) (18)
Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. (2011) (18)
In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole. (1983) (17)
Thiol-related mechanisms of resistance in a murine tumor model. (1994) (17)
Long term effects of radiation and combined modalities on mouse lung. (1986) (17)
Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running (2019) (16)
Enhanced tumor responses through therapies combining CCNU, MISO and radiation. (1984) (16)
A comparison of the pharmacokinetics of multiple and single dose administrations of adriamycin. (1979) (16)
Vascular-Targeted Therapies in Oncology: Siemann/Vascular-Targeted Therapies in Oncology (2006) (15)
Therapeutic strategies that selectively target and disrupt established tumor vasculature. (2004) (15)
The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment. (1994) (15)
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion (2019) (15)
Potentiation of combination chemotherapy by nitroheterocyclics. (1988) (15)
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. (2009) (15)
An update on the clinical development of drugs to disable tumor vasculature (2007) (14)
Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. (1998) (14)
In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice. (1985) (14)
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer (2021) (14)
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells (2019) (14)
Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. (1995) (14)
Keynote address: Tissue oxygen manipulation and tumor blood flow (1992) (13)
Combinations of cyclophosphamide and misonidazole in the KHT sarcoma. (1982) (13)
Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069. (1985) (13)
Measurement of proliferation activities in human tumor models: a comparison of flow cytometric methods. (1998) (13)
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole. (1984) (13)
Quantitative changes in the arterial blood gases of mice following localized irradiation of the lungs. (1983) (12)
Cyclophosphamide-induced pulmonary toxicity. (1986) (12)
Do in vitro studies of potential lethal damage repair predict for in situ results? (1989) (12)
Stability and Mobility of Magnetic Nanoparticles in Biological Environments Determined from Dynamic Magnetic Susceptibility Measurements. (2018) (11)
In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. (2014) (11)
Evaluation of cell subpopulations isolated from human tumor xenografts by centrifugal elutriation. (1990) (11)
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. (2013) (11)
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. (2012) (10)
Pulmonary toxicity following multi-fraction radiotherapy (1986) (10)
Cathepsin L secretion by host and neoplastic cells potentiates invasion (2019) (10)
A human colon adenocarcinoma xenograft--radiation response, cellular composition, and tumor disaggregation. (1987) (10)
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. (2009) (9)
Survival in subpopulations of cells derived from solid KHT sarcomas by centrifugal elutriation following treatment with CCNU and MISO. (1984) (9)
Investigations of perfusion-limited hypoxia and oxygenation in the KHT sarcoma. (1994) (9)
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). (2009) (9)
Tumor Microenvironment: Siemann/Tumor Microenvironment (2010) (9)
Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (I). Centrifugal elutriation. (1987) (9)
154 The VEGFR-2 tyrosine kinase inhibitor, ZD6474, enhances the (2004) (8)
Responses of tumor cell subpopulations to single modality and combined modality therapies. (1988) (8)
Fused pyrazine mono‐N‐oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo (1995) (8)
Effect of thiol manipulation on chemopotentiation by nitroimidazoles. (1989) (8)
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach. (2004) (7)
The effect of chronic reductions in the arterial partial pressure of oxygen on the radiation response of an experimental tumour. (1978) (7)
Effects of ionizing radiation on the adhesive interaction of human tumor and endothelial cells in vitro (2004) (7)
Animal age: a factor influencing the time of death following local thoracic irradiation. (1979) (7)
Combinations of CCNU, MISO, and fractionated radiotherapy. (1986) (7)
Small-Molecule Vascular Disrupting Agents in Cancer Therapy (2008) (7)
Src-signaling interference impairs the dissemination of blood-borne tumor cells (2012) (7)
In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145. (1994) (7)
Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics. (2020) (7)
Modification of Oxygen Supply (2000) (7)
Combined Modality Approaches Using Vasculature‐disrupting Agents (2006) (7)
Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats. (2019) (7)
Modification of cyclophosphamide-induced pulmonary toxicity in normal mice. (1988) (7)
Chemopotentiation in vivo: no loss of sensitization with fractionation. (1984) (7)
The Role of Cathepsins in the Growth of Primary and Secondary Neoplasia in the Bone (2020) (7)
In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines. (1983) (7)
Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination. (1986) (6)
Activity of Bioreductive Agents in Human and Rodent Tumor Cells (1990) (6)
Validation of Alternative Methods (1994) (6)
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model. (2018) (6)
Vascular Disrupting Agents (2007) (6)
Combined Ang-2 and VEGF Targeting Therapies in Renal Cell Carcinoma (2013) (6)
Evaluations of the Renal Cell Carcinoma Model Caki-1 Using a Silicon Based Microvascular Casting Technique (2006) (6)
The in situ tumour response to combinations of cyclophosphamide and tirapazamine. (1996) (6)
Activity off etoposide (VP‐16) and teniposide (VM‐26) in exponential and plateau phase human tumor cell cultures (1992) (6)
Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine. (1983) (6)
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices (2021) (6)
Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice (2021) (5)
Tumour size: a factor influencing the isoeffect analysis of tumour response to combined modalities. (1980) (5)
Impact on Radiotherapy (2010) (5)
Are direct measures of tumor oxygenation reflective of changes in tumor radiosensitivity following oxygen manipulation? (1995) (5)
Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. (2006) (5)
Hypoxia, Metastasis, and Antiangiogenic Therapies (2014) (5)
Separation of Malignant Cells from Host Cells Using Centrifugal Elutriation (1987) (5)
The Microenvironment in Cancer (2010) (4)
Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling (2021) (4)
Therapeutic Modification of Hypoxia. (2021) (4)
Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors. (1992) (4)
The response of mouse lung tumors to combinations of CCNU and misonidazole. (1982) (4)
Towards an integrative understanding of cancer mechanobiology: calcium, YAP, and microRNA under biophysical forces. (2022) (4)
Cytotoxicity of dual function nitrofurans in rodent and human tumor cells. (1992) (4)
The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry. (1984) (4)
3. ROLE OF CARBOGEN IN THE TREATMENT OF HEAD AND NECK CANCER (1999) (4)
Characterizing the Tumor Response to CA4P Treatment (2008) (4)
Cell Proliferation Index Determination by Immunohistochemical Detection of hCDC47 Protein (2010) (3)
Characterization of growth and radiation response of KHT tumor cells metastatic from lung to ovary and kidney (2004) (3)
Does neck stage predict local control after irradiation for head and neck cancer? (1996) (3)
The 93rd Annual Meeting of the American Association for Cancer Research (2002) (3)
Potentials and Limitations for the Use of Radiation Sensitizers of Resistant Hypoxic Cells in Tumors (1983) (3)
The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. (1989) (3)
Dose-effect relationship for surfactant alveolar levels after pulmonary irradiation (1980) (3)
Abstract 4185: Role of Cathepsin L in breast cancer angiogenesis (2015) (2)
Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells (2011) (2)
Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model (2014) (2)
Tissue oxygen manipulation and tumor blood flow. (1992) (2)
Impact of VEGF expression on the physiological characteristics of clonal cell lines. (2006) (2)
Abstract B151: Src inhibitor dasatinib reduces the metastatic phenotype of breast cancer cells. (2011) (2)
Vascular development in mouse lung metastases. (2012) (2)
Significance of the Tumour Microenvironment in Radiotherapy (2009) (2)
Recovery ofcell subpopulations fromhumantumour xenografts following dissociation withdifferent enzymes (1986) (2)
Another road leads to HIF-1 activation: implications for prostate cancer progression. (2012) (2)
Activity of etoposide (VP-16) in human tumor cells under different growth conditions. (1991) (2)
Evaluation of CCNU and Misonidazole in the Treatment of Advanced Colorectal Cancer (1987) (2)
Adeno-associated virus mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo (2003) (2)
Abstract B107: Targeting metastatic tumor cell functions by Src signaling interference using the small molecule Src inhibitor, saracatinib (AZD0530) (2009) (2)
Abstract 5211: In vivo fluorescence and spectral microscopy of the effects of aerobic exercise on tumor oxygenation and perfusion in breast cancer (2015) (2)
Potentiation of CCNU activity by misonidazole in metastases (2004) (1)
Abstract 485: Hypoxia increases the expression of stem-cell markers and promotes cell invasion in prostate cancer cells (2011) (1)
Abstract 5913: The impact of daily exercise on tumor perfusion (2017) (1)
Abstract 1422: Abrogation of prostate cancer cell metastatic phenotype by cathepsin-L inhibition (2011) (1)
Basic fibroblast growth factor antisense oligonucleotides inhibit renal cell carcinoma cell growth and angiogenesis (2003) (1)
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 (2012) (1)
Abstract 4030: In-vivo evaluation of the anti-metastatic efficacy of small molecule Cathepsin L inhibitor KGP94 in a prostate cancer model (2014) (1)
Abstract 2792: Impact of hypoxia on tyrosine kinase activation in cancer cells (2016) (1)
Abstract B24: Impact of aerobic exercise on tumor oxygenation and perfusion in breast cancer (2015) (1)
AI-24VEGFR INHIBITORS ENHANCE PROGRESSION OF GLIOBLASTOMA BY UPREGULATING CXCR4 IN A TGFβR SIGNALING-DEPENDENT MANNER (2014) (1)
FGF7 peptide (FGF7p) mimetic mitigates bladder urothelial injury from cyclophosphamide (2022) (1)
Abstract A23: A novel tumor microenvironment model that combines bioprinting and tissue culture to investigate cancer cell and microvascular interactions (2020) (1)
Acute exercise increases prostate tumor blood flow in rats (2012) (1)
Influence of mode of growth of emt-6 tumor cells on response to adriamycin. Abstr. (1978) (1)
Tumor Vasculogenesis Can Be Derived from the Hematopoietic Stem Cell. (2006) (1)
470 E-cadherin plasticity in tumor-initiating stem-like cells regulates prostate cancer cell invasion (2010) (1)
Abstract B59: Dual mTOR kinase inhibitor reverses rapamycin resistance in prostate cancer cells (2015) (1)
Depletion oftumour versus normal tissue glutathione bybuthionine sulfoximine (1987) (1)
Abstract B150: Cathepsin L targeting abrogates tumor microenvironment enhanced metastatic potential in prostate cancer cells. (2011) (1)
In vivo spectral and fluorescence imaging microscopy of tumor microvessel blood supply and oxygenation changes following vascular targeting agent treatment (2012) (1)
Immunological responses to two different models of micrometastases of a mouse tumor (1978) (1)
Abstract 732: The impact of aerobic exercise on the tumor microenvironment (2016) (1)
The early release of surfactant as a predictor of later lethal radiation pneumonitis (1981) (1)
Angiogenesis and Lung Cancer (2011) (1)
All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System. (2021) (1)
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94 (2016) (0)
1 The Microenvironment in Cancer (2010) (0)
27 Molecular modulation of the tumor vasculature — Impact on tumor response to radiation therapy (2006) (0)
WE‐C‐ValB‐01: Introduction (2006) (0)
Abstract 905: Investigating the effects of aerobic exercise on preclinical breast cancer outcomes (2021) (0)
575 POSTER Targeting metastatic tumor cell functions by inhibition of new blood vessel formation with the selective VEGF signal inhibitor, cediranib (RECENTIN™, AZD2171) or Src signaling interference using the small molecule Src inhibitor, AZD0530 (2008) (0)
Abstract A04: Is the lack of clinical success with antiangiogenic therapy due to vascular normalization not being a universal phenomenon? (2015) (0)
Abstract C190: BMS‐777607, a potent small molecule c‐MET inhibitor, inhibits prostate cancer progression in vitro (2009) (0)
A Novel Tumor Microenvironment Model that Combines Bioprinting and Tissue Culture to Investigate Cancer Cell and Microvascular Interactions (2020) (0)
Abstract A5: Functional role of SOX2 in hypoxia-mediated metastasis-associated functions in prostate cancer (2013) (0)
Abstract 4102: Effect of HGF concentrations on c-Met inhibition investigation (2016) (0)
Author reply (0)
Abstract 2849: Axl: A promising therapeutic target that leads to multimodal inhibition of the metastatic pathway (2019) (0)
Abstract 5094: Angiopoietin-2 antagonist enhances the anti-angiogenic effect of sunitinib in a preclinical renal cell carcinoma model. (2013) (0)
Abstract B157: Effect of HGF concentration on c-Met phosphorylation and inhibition in paracrine-activated tumor cells (2018) (0)
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells (2013) (0)
Abstract 186: Small-molecule inhibition of cathepsins L and K as potential therapeutics for macrophage-driven breast cancer (2018) (0)
Targeting metastatic tumor cell functions by inhibition of Src signaling using the small molecule Src inhibitor, AZD0530 (2007) (0)
Metastatic spread from lung tumors to ovaries and kidneys in c3h mice. Abstr. (1983) (0)
Abstract 3761: Efficacy of the ATP-competitive mTOR inhibitor AZD8055 in PTEN-wild type cancer cells (2012) (0)
Invivo therapeutic potential ofcombination thiol depletion andalkylating chemotherapy (1993) (0)
Opimum pre-irradiation breathing times of 100 percent 02 and 5 percent c02. 95 Percent 02 for a murine sarcoma. Abstr. (1976) (0)
Hyperthermic enhancement of nitroimidazole chemopotentiation: In vitro data, ultrastructural observations, and a pilot flow assessing membrane injury. (Project supported by a 1988–1989 ASTRO fellowship grant) (1989) (0)
Abstract 3759: Host and neoplastic cell secretions of proteolytic enzymes potentiate metastasis (2019) (0)
Abstract 5180: Effects of soy isoflavones and SRC inhibitors on metastatic activity in prostate cancer (2017) (0)
Characterization ofradiation resistant hypoxic cellsubpopulations in KHT sarcomas.(ii) Cellsorting (1988) (0)
The Role of Amifostine as a Radioprotector (2017) (0)
Abstract B013: Combined molecular targeting Src and mTOR pathways to impair prostate cancer cell survival (2018) (0)
2090 TL1 team approach to osteosarcoma cell detection (2018) (0)
Toxicity of the Hoechst 33342 Stain in Untreated or Irradiated Murine Tumor Cells 1 (2006) (0)
Potential therapeutic gains from combinations of certain radiosensitizers and chemotherapeutic agents (1980) (0)
Abstract 2952: The novel cathepsin L/K inhibitors KGP94 and KGP207 prevent M0 to M2 macrophage differentiation and macrophage-mediated pro-tumor functions (2017) (0)
Spectral imaging of microvascular function in a renal cell carcinoma after treatment with a vascular disrupting agent (2009) (0)
Abstract 4518: Impact of hypoxia on SFK activities in prostate cancer cells (2017) (0)
Enhancement ofchemotherapy andnitroimidazole-i nduced chemopotentiation bythevasoactive agenthydralazine (1990) (0)
Areviewandupdateof thecurrentstatusofthe vasculature-disabling agentcombretastatin-A4 phosphate(CA4P) (2009) (0)
Abstract 3063: Predicting efficacy of c-Met targeting therapy in autocrine and paracrine tumor cell lines (2017) (0)
Abstract 3946: Saracatinib inhibits human prostate cancer cell bone metastases in a xenograft model. (2013) (0)
Abstract 6114: Host and neoplastic cells utilize Axl for breast cancer bone metastasis (2020) (0)
The importance of pharmacokinetic alterations and hypoxia in the potentiation of chemotherapeutic agents by radiation sensitizers. Abstr. (1982) (0)
Author's response to reviews Title: Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 Authors: (2012) (0)
3357 TL1 Team Approach to Using a Combination of Ganglioside 2 and 3 as an Immunoaffinity Target for Circulating Osteosarcoma Cell Detection (2019) (0)
Oxidative stress regulates expression of VEGFR1+ in myeloid cells: Link to angiogenesis and tumor-induced immune suppression in renal cell carcinoma (2008) (0)
nitrosourea in the Absence or Presence of Misonidazole in Mice 1 (2006) (0)
DualTargetingofTumorVasculature:CombiningAvastinand VascularDisruptingAgents(CA4PorOXi4503) (2008) (0)
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells (2011) (0)
Introduction: Drug/radiation therapy interactions (2003) (0)
P29 19 WP – RADIATION RESPONSE IN A DRUG RESISTANT TUMOR CELL LINE (1991) (0)
Hypoxic cells andinsitu chemopotentiation (1984) (0)
Abstract 4122: C-Met inhibition sensitivity in vitro: Autocrine vs. paracrine activation of the c-Met pathway (2015) (0)
Abstract 3154: Host and neoplastic cell Axl inhibition impair prostate and breast cancer bone metastasis (2021) (0)
P38 34 TP – THE EFFECT OF VARIOUS RADIOSENSITIZING AGENTS ON TUMOUR BLOOD PERFUSION (1991) (0)
Abstract B02: Combined inhibition of mTOR and Src family kinases enhances treatment effects in prostate cancer cells (2020) (0)
Smoking. A possible factor affecting the tumor response to radiotherapy. Abstr. (1977) (0)
Abstract 2507: Axl suppression inhibits cell migration, invasion and survival in breast and prostate cancer cell lines (2018) (0)
Abstract 2441: Effects of hypoxia on Src family members' activity in prostate cancer cells (2018) (0)
Abstract 1425: Impact of VEGFR pathway inhibition on the expression and function of CXCR4 in primary patient derived glioblastoma cell lines. (2013) (0)
Realizations of vascularized tissues: From in vitro platforms to in vivo grafts. (2023) (0)
Fractionation: Biology applied to the clinical radiotherapy (1998) (0)
N-oxide derivatives of chlorambucil as agents for overcoming hypoxic cell radiation resistance (1997) (0)
SU‐FF‐T‐330: Optimal Dose Fractionation Schedules Computed with Different Tumor Reoxygenation Rates (2007) (0)
A MURINE XENOGRAFT MODEL OF CANINE OSTEOSARCOMA: (2007) (0)
Abstract 5431: FGF7 peptide (FGF7p) mimetic mitigates urothelial injury from cyclophosphamide or radiation (2022) (0)
74 Enhancement of radiation damage in murine tumours and normal tissues using clinically relevant doses of nicotinamide (1996) (0)
Abstract B5: Tumor-cell-induced angiopoietin-2 secretion from endothelial cells results in destabilization of the endothelial/smooth muscle cell interaction of blood vessels. (2011) (0)
Monitoring Tumor Therapy (2013) (0)
Abstract 777: Effects of Src inhibitors and soy isoflavones on human prostate cancer cells (2015) (0)
International Conference on Vascular Targeting (2002) (0)
Abstract 660: Combination of mTOR kinase inhibitors with Src inhibitors in PTEN-mtprostate cancer cells (2020) (0)
Abstract 4899: The small molecule cathepsin L and K inhibitor KGP-94 impairs the metastatic phenotype of osteosarcoma cells (2017) (0)
Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94 (2014) (0)
Monoclonal Antibodies Against 4-1BB Enhance the Antitumor Effects of Radiation (2004) (0)
Abstract 3578: Dual mTOR kinase inhibitor overcomes rapamycin resistance in vitro (2015) (0)
Novobiocin , an Inhibitor of Mammalian Topoisomerase II Adriamycin and 4-Hydroperoxycyclophosphamide by Modulation of the Cell Cycle-dependent Cytotoxicity of Updated Version (2006) (0)
All-optical mechanobiology interrogation of YAP in human cancer and normal cells using a novel multi-functional system (2021) (0)
dilation in the rat spinotrapezius muscle Exercise training enhances adrenergic constriction and (2015) (0)
Combination of ccnu and radiosensitizers in vivo: misonida- zole and benzindazole. Abstr. (1982) (0)
Abstract 4037: Combining tyrosine kinase inhibitors and isoflavones to target metastatic activity in prostate cancer cells (2014) (0)
Abstract 5507: Activation of a subset of growth factor-associated genes in cetuximab-sensitive colorectal cancer GEO cells with KRAS mutation (2014) (0)
Abstract 3914: mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells (2019) (0)
Time and dose dependent vascular effects of NPI-2358 in mouse tumour models (2010) (0)
permissive trigger neovasculogenesis is dependent on model system with SDF-1 as a Bone marrow stem and progenitor cell contribution to (2012) (0)
Abstract A33: Small molecule cathepsin L inhibitor KGP94 suppresses hypoxia and acidosis potentiated metastatic capacity of prostate and breast cancer cells (2013) (0)
Calendar (1991) (0)
Renal Cell Carcinoma Tumor-Induced Immune Suppression in VEGFR 1 in Myeloid Cells : Link to Oxidative Stress Regulates Expression of and Johannes Vieweg (2008) (0)
Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture (1992) (0)
The Hematopoietic Stem Cell Is a Source of Endothelial Cells in Cancer Vasculogenesis and Depends on SDF-1. (2007) (0)
Abstract 5357: mTOR kinase inhibitor AZD8055 reverses acquired rapamycin resistance in prostate cancer cells (2022) (0)
519 Preclinical evaluation of the second generation vascular disrupting agent OXI 4503 (2004) (0)
Neurotoxicity of combinations of misonidazole and five antitumor drugs in mice. Abstr. (1982) (0)
Abstract 5093: Tumor angiogenesis: The role of Cathepsin L and its therapeutic intervention by the small molecule inhibitor KGP94. (2013) (0)
Src-signaling interference impairs the dissemination of blood-borne tumor cells (2012) (0)
Abstract 3923: Insensitivity to c-Met inhibition at physiologic HGF concentrations in a prostate carcinoma model (2018) (0)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation (2012) (0)
Abstract 2965: Aerobic exercise delays intraductal breast cancer growth and suppresses doxorubicin-induced skeletal and cardiac muscle toxicities (2020) (0)
Abstract 4269: Human monoclonal anti-angiopoietin-2 antibody, MEDI3617, inhibits angiogenesis in preclinical studies (2011) (0)
AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab. (2009) (0)
OXI 4503-second generation vascular targeting agent: Histopathologic changes and preclinical efficacy (2004) (0)
Abstract 927: Combined targeting c-Src and c-Met pathways to impair prostate cancer cell growth and invasion. (2013) (0)
The effect of exposing tumor-bearing mice to a reduced oxygen environment prior to but not during irradiation. Abstr. (1978) (0)
The role of TGFβ in driving early cystic fibrosis lung disease (2018) (0)
The Effects of the Anti-Cancer Agent Dasatinib on KHT Murine Sarcoma Cells (2011) (0)
XBP-1 Is Essential for Tumor Angiogenesis in MEF Cells and in Human Fibrosarcoma HT 1080 Cells (2009) (0)
Abstract 3198: The impact of aerobic exercise on oxygenation and vascularity in breast cancer models (2015) (0)
Abstract 4495: Treatment effects of the novel mTOR kinase inhibitor AZD8055 in prostate cancer cell models (2011) (0)
Abstract 1477: Co-targeting c-Met and c-Src pathways to inhibit metastatic cancer cell migration and invasion (2021) (0)
Abstract 5071: KGP94, a small-molecule cathepsin L inhibitor with antitumor activity. (2013) (0)
Role of vascular dysfunction in prostate tumor perfusion during exercise (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dr. Dietmar W. Siemann?

Dr. Dietmar W. Siemann is affiliated with the following schools:

Dr. Dietmar W. Siemann's Academic­Influence.com Rankings

Why Is Dr. Dietmar W. Siemann Influential?

Dr. Dietmar W. Siemann's Published Works

Published Works

What Schools Are Affiliated With Dr. Dietmar W. Siemann?

Dr. Dietmar W. Siemann's AcademicInfluence.com Rankings